{
    "clinical_study": {
        "@rank": "33624", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 LY2944876", 
                "arm_group_type": "Experimental", 
                "description": "Dose 1 of LY2944876 given subcutaneously (SC) once weekly for 24 weeks."
            }, 
            {
                "arm_group_label": "Dose 2 LY2944876", 
                "arm_group_type": "Experimental", 
                "description": "Dose 2 of LY2944876 given SC once weekly for 24 weeks."
            }, 
            {
                "arm_group_label": "Dose 3 LY2944876", 
                "arm_group_type": "Experimental", 
                "description": "Dose 3 of LY2944876 given SC once weekly for 24 weeks."
            }, 
            {
                "arm_group_label": "Dose 4 LY2944876", 
                "arm_group_type": "Experimental", 
                "description": "Dose 4 of LY2944876 given SC once weekly for 24 weeks."
            }, 
            {
                "arm_group_label": "Exenatide extended-release", 
                "arm_group_type": "Experimental", 
                "description": "2 milligrams (mg) exenatide extended-release given SC once weekly for  24 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo  for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to compare the safety and effectiveness of the study drug\n      known as  LY2944876 to exenatide extended-release and placebo in participants with type 2\n      diabetes mellitus. All drugs will be given by an injection under the skin. Participants\n      remain on stable doses of metformin, as prescribed by their personal investigator if they\n      were on metformin at study entry. Participants involvement in the study is expected to last\n      about 30 weeks."
        }, 
        "brief_title": "A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will include a 12 week blinded treatment period, where neither the participant nor\n      the investigator will know to which treatment each individual is assigned. Thereafter\n      follows a 12 week period where participants and the investigator will know which treatment\n      they are assigned to. Participants on LY2944876 and on exenatide extended-release continue\n      treatment in this period, those who received placebo will be followed without treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women with diabetes mellitus Type 2\n\n          -  Have screening HbA1c \u22657.0% and \u226410.5% either on diet and exercise alone or on a\n             stable dose of metformin (\u22651000 mg/day) for 3 months prior to screening\n\n          -  Have body mass index (BMI) \u226523 and \u226445 kilograms per meter squared at screening\n\n        Exclusion Criteria:\n\n          -  Women of child bearing potential\n\n          -  Participants who have used thiazolidinediones within 3 months prior to screening, or\n             any other drugs for treatment of hyperglycemia (except metformin) within the prior 2\n             months\n\n          -  Participants who have used insulin for diabetic control for more than 6 consecutive\n             days within the prior year\n\n          -  Participants with impaired renal function (serum creatinine >124 micromole per liter\n             (\u00b5mol/L)  [1.4 milligrams per deciliter (mg/dL)] in women, >133 \u00b5mol/L [1.5 mg/dL] in\n             men)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "375", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119819", 
            "org_study_id": "15062", 
            "secondary_id": [
                "2013\u2010003552\u201021", 
                "I7I-MC-XNAA"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose 1 LY2944876", 
                    "Dose 2 LY2944876", 
                    "Dose 3 LY2944876", 
                    "Dose 4 LY2944876"
                ], 
                "description": "Administered SC", 
                "intervention_name": "LY2944876", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Exenatide extended-release", 
                "description": "Administered SC", 
                "intervention_name": "Exenatide extended-release", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered SC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Weight loss", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Nashua", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03063-4068"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Greece: National Organization of Medicines", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Hemoglobin A1c (HbA1c) at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119819"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in HbA1c at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Mean Percent Change from Baseline in Body Weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Fasting Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Lipids", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Fasting Fibroblast Growth Factor 21", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Percentage of Participants Requiring Rescue Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Therapy Completion (Week 24)"
            }, 
            {
                "measure": "Percentage of Participants Developing Anti-Drug Antibodies to LY2944876 or Polyethylene Glycol", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Therapy Completion (Week 24)"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2944876", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Therapy Completion (Week 24)"
            }, 
            {
                "measure": "Change from Baseline in Adiponectin Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Beta-Hydroxy Butyrate Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Glucagon Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Change from Baseline in Insulin Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876", 
                "safety_issue": "No", 
                "time_frame": "Time Frame: Baseline through Therapy Completion (Week 24)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}